<DOC>
	<DOC>NCT00115375</DOC>
	<brief_summary>PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet aggregation similar to adults.</brief_summary>
	<brief_title>Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)</brief_title>
	<detailed_description>There will be 3 blinded dose groups of 12 patients each (9 active, 3 placebo), central randomization, stratified by age (&lt; 1 month ;1 to 24 months). There will be a comparison of ADP-induced platelet aggregation at steady state.</detailed_description>
	<mesh_term>Heart Defects, Congenital</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Neonates or infants/toddlers (up to 24 months) at risk for thrombosis (e.g., BlalockTaussig shunt or any systemic to pulmonary artery shunt, Kawasaki disease, vascular stent or any condition requiring antiplatelet therapy). Ongoing bleeding or increased risk of bleeding Weight &lt; 2 kg; gestational age &lt; 35 weeks Allergy to drugs Current or planned anticoagulant treatment Unable to receive drug enterically Platelet transfusion &lt; 7days Thrombocytopenia Hepatic or renal failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>THROMBOSIS</keyword>
	<keyword>PLATELET AGGREGATION</keyword>
	<keyword>Pediatrics</keyword>
</DOC>